Seventure and minority shareholders have sold TargEDys to Biocodex


TargEDys is an innovative French biotechnology that is pioneering disruptive microbiome-based solutions, mainly addressing weight management, growth and anxiety health challenges. The company develops and provides unique next-generation precision probiotic solutions, presenting detailed mechanism of actions and proven in-vivo efficacy.

The Deal

With the support of Biocodex, TargEDys will continue its ambitious growth strategy of developing a multi-technology scalable platform and investing in science.

Our Perspective

This transaction further adds to Lincoln International’s track-record in microbiome and consumer healthcare space.

Connect with a Senior Team Member

Meet our Senior Team

Any information or testimonials contained in this post may not be representative of the experience of other clients and is no guarantee of future performance or success.